vatalanib
An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.
| Synonym: | CGP79787D PTK787/ZK 222584 |
|---|---|
| Code name: | CGP-79787 PTK787 ZK 222584 |
| Chemical structure: | 1-[4-Chloroanilino]-4-[4-pyridylmethyl]phthalazine Succinate 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, butanedioate (1:1) |
| NSC code: | 719335 |